PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the appointment of ...

Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, and ...

Reports Q1 revenue $, consensus $. “We have made strides in our Phase 1 SB101 trial with established clinical benefit including a 45% reduction ...

Sonnet BioTherapeutics (SONN) announced the appointment of Stephen McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025.

The upgraded Claude 3.5 Sonnet, the latest and most intelligent model in the Claude model family from artificial intelligence ...

Sonar is built on top of Meta’s open-source Llama 3.3 70B. It is powered by Cerebras Inference, which claims to be the ...

The company claims its newly upgraded model is number one in user satisfaction and speed - but its methodology is unclear.

Alibaba’s innovations in AI and cloud computing offer strong returns. Learn why BABA stock remains undervalued with ...

PRINCETON - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage biotechnology company specializing in immunotherapy treatments with a current market capitalization of $4.69 million, ...

Sonnet's F H AB platform consists of a single, fully human construct of a F H AB antibody fragment that has high affinity to bind to human albumin. The platform provides an off-the-shelf lock and load ...

Love is 'an ever-fixèd mark.' Kate Moncrief and Brendon Fox - No impediments to this marriage of true minds, true love ...